Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.62 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940856 | 1.00 | MAOB (0.62) | MAOBMAOASCN9AADAMTS4MMP13 | |
| SCHEMBL1672184 | 1.00 | MAOB (0.62) | MAOBMAOASCN9AADAMTS4MMP13 | |
| Water SCHEMBL1672694 | 0.99 | MAOB (0.61) | MAOBMAOASCN9AADAMTS4MMP13 | |
| Water SCHEMBL1672445 | 0.99 | MAOB (0.61) | MAOBMAOASCN9AADAMTS4MMP13 | |
| SCHEMBL6431395 | 0.90 | MAOB (0.61) | MAOBMAOASCN9AADAMTS4MMP13 | |
| SCHEMBL8640665 | 0.89 | MAOB (0.49) | MAOBMAOASCN9ABCHE | |
| SCHEMBL8637848 | 0.89 | MAOB (0.48) | MAOBMAOASCN9ABCHE | |
| SCHEMBL1665416 | 0.88 | MAOB (0.56) | MAOBMAOASCN9AADAMTS4MMP13 | |
| Hydrochloric Acid SCHEMBL8636522 | 0.88 | MAOB (0.48) | MAOBMAOASCN9ABCHE | |
| SCHEMBL2167377 | 0.87 | MAOB (0.50) | MAOBMAOAADAMTS4MMP13BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011047767-A1 | NOVEL POLYMORPHIC FORMS OF (S)-2-[-4-(3-FLUORO-BENZYLOXY)-BENZYLAMINO]-PROPIONAMIDE MESYLATE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2011-04-28 | — | — | WO | claimed |
| EP-2314569-A1 | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof | Merck Patent GmbH (DE) | 2011-04-27 | — | — | EP | claimed |
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | disclosed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | disclosed |
| EP-2474521-B1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | disclosed |
| EP-2029524-B1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | NEWRON PHARM SPA (IT) | 2014-11-26 | — | — | EP | disclosed |
| US-8846763-B2 | High purity 2-[4-(3- or 2-fluorobenzyloxy)benzylamino] propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-09-30 | — | — | US | disclosed |
| US-20140051758-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-02-20 | — | — | US | disclosed |
| US-8530701-B2 | High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2013-09-10 | — | — | US | disclosed |
| US-8278485-B2 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-10-02 | — | — | US | disclosed |
| US-20050026909-A1 | Method of treating lower urinary tract disorders | DYNOGEN, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050020577-A1 | Method of treating lower urinary tract disorders | DYNOGEN, INC. | 2005-01-27 | — | — | US | disclosed |
| US-6846823-B2 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040248979-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004089288-A2 | METHOD OF TREATING LOWER URINARY TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040209869-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004066987-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248979-A1 | Method of treating lower urinary tract disorders | RYR2, CACNA1S, CACNA1D | MAOB 515/4885MAOA 660/4885SCN9A 1931/4885 |
| US-20140051758-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO] PROPANAMIDES AND METHODS OF USE THEREOF | KCNH3, KCNB2, KCNH2 | MAOB 149/4885MAOA 473/4885SCN9A 146/4885 |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, VIPR2, TRPV1 | MAOB 987/4885MAOA 995/4885SCN9A 60/4885 |
| US-20050020577-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, HTR3C | MAOB 9/4885MAOA 15/4885SCN9A 3943/4885 |
| US-20040209869-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, MME | MAOB 8/4885MAOA 13/4885SCN9A 3969/4885 |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | CACNA1G, CACNA1D, CACNA1B | MAOB 845/4885MAOA 983/4885SCN9A 62/4885 |
| US-20050026909-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, HTR3C | MAOB 9/4885MAOA 15/4885SCN9A 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.